F.i.s. Fabbrica Italiana Sintetici S.p.a.

Zambon Group S.p.a.

Zambon S.p.a.

Zach System S.p.a.

Angelo Restelli

Pierluigi Padovan

Paolo Stabile

Matteo De Poli

Livius Cotarca

Nicolas Tesson

Jordi De Mier Vinue

Marco Villa

Franco Pellacini

Mauro Napoletano

Dario Braga

Massimo Verzini

Gabriele Morazzoni

Paolo Maragni

Roberto Giovanetti

Andrea Nicoli

Roberto Brescello

Ivan Michieletto

Dario Tentorio

Stefano Fogal

Franco Massaccesi

Elisa Melotto

Sergio Riva

Alessandro Di Maria

Jordi De Mier Vinué

Dario Università Di Bologna Braga

The present invention relates to a process for the preparation of Droxidopa by means of an improved enzymatic reduction of a compound of formula (II): (II), wherein R, Ris independent hydrogen, acetyl, Ris hydrogen, a C1-C4 linear or branched alkyl group and Ris hydrogen or an amine protecting group. 

Enzymatic process for the preparation of Droxidopa

Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.

Highly stable crystalline Eltrombopag monoethanolamine salt form D1

Object of the present invention is a better crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D, stable, suitable for pharmaceutical purposes, and with the highest solubility in water and excellent non-hygroscopicity, then the related process and intermediates thereof.

Crystalline Eltrombopag monoethanolamine salt form D

The present invention relates to macrolide compounds endowed with antiinflammatory activity and more particularly relates to new stable crystalline forms of a macrolide derivative with antiinflammatory activity, processes for the preparation of such forms, pharmaceutical compositions containing them as active ingredient and the use of said crystalline forms for the treatment of inflammatory diseases.

Crystalline forms of macrolide compounds endowed with antiinflammatory activity

A process for the preparation of gabapentin comprising the passage of a salt of the same through a ionic exchange resin of strong cationic type, the elution of the gabapentin which has fixed onto the column and the crystallization from organic solvent, characterized in that the resin is regenerated by using a mineral acid in a molar quantity between 50 and 90%, is described.

Process for the purification of gabapentin

Process for the enzymatic kinetic resolution of 3-phenylglycidates by transesterification with aminoalcohols

Growing community of inventors

Gerenzano, Italy

Angelo Restelli